Pub. Date : 2018
PMID : 30083256
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Blocking CDK1/PDK1/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. | Sorafenib | cyclin dependent kinase 1 | Homo sapiens |
| 2 | Blocking CDK1/PDK1/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. | Sorafenib | cyclin dependent kinase 1 | Homo sapiens |
| 3 | Mechanistic and functional studies silencing CDK1 with shRNA and RO3306 combined with sorafenib abolished oncogenic function via downregulating CDK1, with downstream PDK1 and beta-Catenin inactivation. | Sorafenib | cyclin dependent kinase 1 | Homo sapiens |
| 4 | Mechanistic and functional studies silencing CDK1 with shRNA and RO3306 combined with sorafenib abolished oncogenic function via downregulating CDK1, with downstream PDK1 and beta-Catenin inactivation. | Sorafenib | cyclin dependent kinase 1 | Homo sapiens |
| 5 | Conclusion: Anti-CDK1 treatment can boost sorafenib antitumor responses in PDX tumor models, providing a rational combined treatment to increase sorafenib efficacy in the clinic. | Sorafenib | cyclin dependent kinase 1 | Homo sapiens |
| 6 | Conclusion: Anti-CDK1 treatment can boost sorafenib antitumor responses in PDX tumor models, providing a rational combined treatment to increase sorafenib efficacy in the clinic. | Sorafenib | cyclin dependent kinase 1 | Homo sapiens |